In this newly created position, Brandon will lead manufacturing and operations at the company's 183,000 square foot Department of Defense Advanced Development and Manufacturing facility in Alachua, Florida.
Prior to joining Ology Bioservices, Brega served in various positions at Merck and Co., most recently as Associate vice president, Plant Management at the company's Durham, North Carolina location the largest vaccines-only facility in Merck's network.
Prior to joining Merck, Brega worked for a number of animal health manufacturers including Pfizer Inc., Wyeth Pharmaceuticals, Boehringer Ingelheim and Merial Ltd., leading operations and technical organizations in the production of vaccines, biologics and sterile injectables.
He has broad base of experience with both drug substance and drug product manufacturing across both small and large molecules.
Brega holds both a Bachelor of Science in Biology and Master of Arts in Management from Doane University and earned a Masters Certification in Six Sigma and Lean Six Sigma Black Belt from Villanova University.
Ology Bioservices serves both government and commercial clients, specialising in biologic drug substance manufacturing, from early stage through commercial product.
The company has 183,000 square feet of manufacturing, process development and QA/QC space in its Department of Defense Advanced Development and Manufacturing Facility in Florida.
GSK and IQVIA expand vaccine track with local data to drive targeted public health action
AstraZeneca launches online platform to expand patient access to medications
Sanofi increases Sanofi Ventures funding by USD625m to boost biotech and digital health investments
GC Biopharma submits IND application in South Korea for Phase 1 trial of COVID-19 vaccine candidate
AusperBio completes patient enrolment in two Phase II clinical trials of AHB-137
LakeShore Biopharma receives Nasdaq delisting determination letter
Valneva reports strong Phase 2 booster results for Lyme disease vaccine candidate VLA15
GC Biopharma files IND for Phase 3 trial of BARYCELA in Thailand
Novavax COVID-19 vaccine approved in US
WHO and UNICEF deploy PharmaJet's Tropis ID system in Afghanistan polio campaign
FDA grants priority review for GSK's gepotidacin gonorrhoea indication